Trump did what he should not have done, and I can no longer support him the way I have for ten years.  It’s time for me to move on to other things and people. To put it mildly, we’re talking about a Tree of Knowledge of Eternal Life issue, where pot is the snake in the garden, trying to push humanity to eat from the Tree of Knowledge of Good and Evil.  God puts all these trees in the garden, but wants human beings to make free choices about what is best.  And this is one of those kinds of issues.   Can a plant be evil?  Sure, it can; the snakes of the world will, of course, say no.  

Donald Trump’s decision to reclassify marijuana from Schedule I to Schedule III is, in my view, a catastrophic mistake. It’s not just a technical change—it’s an open door for the cannabis lobby and progressive forces that have been pushing for mass legalization under the guise of “medical necessity.” This move mirrors the same vulnerability Trump showed during COVID: trusting white-coat experts who present themselves as saviors while advancing agendas that weaken society.

Cannabis is not harmless. It’s a gateway drug, a cognitive depressant, and a cultural detriment. Studies link marijuana use to lower IQ, impaired memory, psychosis, and increased risk of schizophrenia. Emergency room visits and traffic fatalities spike in states after legalization. THC potency has skyrocketed, amplifying addiction and mental health crises. These aren’t fringe claims—they’re documented realities.

The argument that marijuana is needed for pain relief is a false choice. We should be solving cancer and chronic pain at the root, not normalizing an intoxicant tied to decades of social decay and, yes, deeper occult influences that seek to compromise human clarity and autonomy. Legalization advocates have always framed this as compassion, but the real goal is control: a dulled, compliant population.

Trump thinks this is an 85% approval issue. He sees polls, not principles. But leadership isn’t about chasing popularity—it’s about protecting civilization from corrosive forces. On this issue, he failed. For me, it’s a deal-killer. I’ve supported Trump for a decade, but endorsing marijuana—even under the medical banner—is embracing evil. Ohio’s recent rollback of legalization shows the right path: resist the progressive push, restore sanity. Donald Trump’s decision to reclassify marijuana isn’t just bad policy—it’s political deceit. He waited until the Christmas season to slide this under the door, the same way Obama did with Obamacare, hoping conservatives would be distracted. He announced it right after addressing the nation and during the release of the Epstein findings, burying the story behind bigger headlines. That’s not leadership; that’s manipulation.

Why? To appease his new left-leaning allies—the Kennedy health crowd and cannabis advocates who’ve been pushing this agenda for decades. Trump gave them a bone, thinking it would broaden his coalition. But in doing so, he embraced a cultural Trojan horse. And the enemies of our nation are hidden inside, clapping because they see in Trump a sucker they easily manipulated and turned into their weapon of doom.

This isn’t about being rigid; it’s about survival. Drugs erode minds, and compromised minds are easy to control. Trump got played, and America will pay the price if we don’t fight back. What follows may be heavy on the legal terminology and statistics. But the evidence is quite extensive, and for those who need further proof, well beyond just opinion, well, here it is:

On December 18, 2025, President Donald J. Trump signed an executive order directing federal agencies to expedite the rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA), the most consequential U.S. cannabis policy shift in over half a century (White House Fact Sheet, 2025; POLITICO, 2025). The action accelerates a process begun after the Department of Health and Human Services (HHS) recommended Schedule III in August 2023 and the Drug Enforcement Administration (DEA) issued a Notice of Proposed Rulemaking in May 2024 (CRS, 2023; DEA, 2024). While rescheduling may ease research constraints and alter tax treatment, it does not legalize recreational use nor eliminate associated public-health risks (POLITICO, 2025; All About Lawyer, 2025). But it is an open door to the pot advocates which is trying to ignore the evidence on neurocognitive outcomes, addiction epidemiology, psychosis risk, pediatric exposures and emergency presentations, and traffic safety to assess ethical and policy implications—using Ohio’s late-2025 legislative retrenchment as a case example (Ohio Capital Journal, 2025; Cincinnati Enquirer/USA Today, 2025).

President Trump’s order directs the Attorney General to complete rescheduling to Schedule III, aligning with HHS’s 2023 scientific review that recognized currently accepted medical uses for marijuana (White House Fact Sheet, 2025; CRS, 2023). Media and legal analyses concur that the order expedites but does not itself finalize DEA rulemaking—and thus does not legalize adult-use marijuana at the federal level (POLITICO, 2025; All About Lawyer, 2025). The DEA’s 2024 proposed rule explicitly states that even if marijuana moves to Schedule III, manufacture, distribution, and possession remain subject to applicable controls, and FDA drug-approval requirements still apply (DEA, 2024). At the same time, the executive order frames rescheduling as a research- and access-facilitating initiative (White House Fact Sheet, 2025).  Which I propose is a declining state of any nation, once that path is opened to public acceptance.

2.1 Longitudinal Evidence of Cognitive Decline, the Dunedin cohort (n≈1,037) provides prospective evidence: persistent cannabis use beginning in adolescence was associated with an average drop of ~8 IQ points between ages 13 and 38, with broad impairments in memory and executive functions; reductions were not fully reversed by cessation (Meier et al., 2012; Nature News, 2012).

2.2 Methodological Challenges and Confounding, critics argue that socioeconomic and familial confounders may explain part or all of the observed IQ decline, warning against strong causal claims from observational data (Rogeberg, 2012).

2.3 Consensus Reviews. Authoritative reviews conclude that regular adolescent use is associated with deficits in learning, attention, and memory, with stronger evidence for harms among youths (Volkow et al., 2014 NEJM).

Cannabis can lead to clinically significant use disorders. Classic estimates report ~9% dependence among experimenters, rising to ~17% for adolescent initiators and 25–50% for daily users (Volkow et al., 2014). JAMA Psychiatry analyses found that past-year marijuana use doubled from 4.1% (2001–2002) to 9.5% (2012–2013), and nearly 3 in 10 users met criteria for a marijuana use disorder; overall past-year cannabis use disorder prevalence reached ~2.8% of U.S. adults (Hasin et al., 2015; Columbia Mailman School release, 2015). Prospective U.S. data link baseline cannabis use to elevated odds of subsequent alcohol, cannabis, other drug use disorders, and nicotine dependence, even when adjusting for extensive confounders (Blanco et al., 2016).

Case-control and multicenter studies associate daily use—especially of high-potency cannabis—with substantially higher odds of first-episode psychosis (adjusted OR ≈3.2 for daily use; ≈4.8 for daily high-potency), and estimate population-attributable fractions up to ~30% in London and ~50% in Amsterdam under high-potency exposure scenarios (Di Forti et al., 2019; King’s College London, 2019). Danish nationwide registry analyses (n>7 million) report that the fraction of schizophrenia cases attributable to cannabis use disorder rose from ~2% (mid-1990s) to ~6–8% since 2010; among young males, PARF estimates reach ~15% by 2021 (Hjorthøj et al., 2021; Hjorthøj et al., 2023). Critiques caution that genetic and environmental confounding may inflate causal interpretations; however, registry time-trend analyses and sensitivity checks strengthen the case that rising potency and heavy use contribute materially (Gillespie et al., 2019; ESPE Yearbook summary, 2022).

Following legalization in Colorado, pediatric poison-center calls and hospital visits for marijuana exposures increased, with edibles frequently implicated; rates roughly doubled in hospital data and quintupled in poison-center reports from 2009 to 2015 (Wang et al., 2016 JAMA Pediatrics; ScienceDaily, 2016). Subsequent analyses through 2017 confirmed continued increases despite packaging reforms (Clinical Pediatrics, 2019). Recent U.S. pediatric hospital-system data (2016–2023) show sharp rises in adolescent cannabinoid hyperemesis syndrome (CHS) emergency-department encounters, with higher rates in recreational-legal states, though increases occur in both legal and non-legal settings (Toce et al., 2025).

Meta-analyses indicate that acute cannabis use is associated with increased motor-vehicle crash risk—approximately 1.2–1.9 times higher odds overall, with stronger associations in fatal collisions and case-control designs; combined alcohol and THC further magnifies risk (Asbridge et al., 2012 BMJ; Rogeberg & Elvik, 2016 Addiction). Updated reviews summarize impairments in reaction time, attention, and lane keeping, and recommend conservative post-use waiting windows (≈6–8 hours inhaled; ≈8–12 hours oral) (Cannabis Evidence, 2025).

In December 2025, Ohio enacted SB 56, banning most intoxicating hemp outside licensed dispensaries, vetoing THC beverages, lowering THC caps, criminalizing possession of products purchased in other states, and tightening public-use rules—changes framed as child-safety and regulatory harmonization (Ohio Capital Journal, 2025; Cincinnati Enquirer/USA Today, 2025). Reporting notes that the law rolls back portions of the voter-approved 2023 statute (Issue 2) and may trigger legal and political challenges (WLWT, 2025; NORML, 2025). Ohio’s trajectory exemplifies how states recalibrate post-legalization to address pediatric exposures, product potency, interstate transport, and community norms (Statehouse News Bureau, 2025; APA Ohio summary of Issue 2, 2023).

Respect for autonomy is constrained by predictable harms to minors, vulnerable populations, and public safety. The empirical record—rising adolescent CHS encounters, increased unintentional pediatric ingestions, measurable crash-risk elevations, and signals linking heavy/high-potency use to psychosis—supports precautionary regulation even as research into therapeutic cannabinoids proceeds (Toce et al., 2025; Wang et al., 2016; Asbridge et al., 2012; Di Forti et al., 2019).

• Age-targeted prevention and potency controls: Restrict high-potency products for adolescents and young adults; fund longitudinal potency-exposure surveillance (Di Forti et al., 2019; Hjorthøj et al., 2023).

• Packaging, retail, and home-storage safeguards: Enforce child-resistant, opaque packaging; limit candy-like edibles; and conduct statewide campaigns on home storage (Wang et al., 2016; Clinical Pediatrics, 2019).

• Clinical readiness for CHS and psychosis: Resource EDs with CHS protocols; ensure early detection and treatment pathways for cannabis-associated psychosis, especially for young males (Toce et al., 2025; Hjorthøj et al., 2023).

• Impaired-driving enforcement and guidance: Invest in drug-recognition training, public messaging on waiting windows post-use, and integrated alcohol-THC deterrence strategies (Asbridge et al., 2012; Rogeberg & Elvik, 2016).

• Research integrity post-rescheduling: Use Schedule III easing to fund randomized trials and mechanistic studies; maintain transparency about limitations of observational data (White House Fact Sheet, 2025; CRS, 2023).

Rescheduling marijuana to Schedule III is a structural change that may boost research and alter industry economics—but epidemiologic signals argue for a prudential approach prioritizing youth protection, potency regulation, impaired-driving prevention, and clinical readiness for CHS and psychosis. The Ohio experience demonstrates that, after initial liberalization, states often recalibrate to safeguard public health. Policymakers should balance putative benefits against quantifiable risks, keeping protection of the vulnerable at the center of cannabis governance (Ohio Capital Journal, 2025).

The data piles on: youth brain changes from cannabis are lasting, altering connectivity in executive networks and reducing hippocampal volume.[11] Gateway effects, though debated, show associations where cannabis precedes harder drugs in sequences, with some studies finding fivefold increases in likelihood.[12] Societal costs mount—emergency visits for hyperemesis and psychoses rise, impaired driving fatalities involving THC climb post-legalization, and cognitive deficits compound into lifelong disadvantages.  So, in many ways, marijuana is a gateway drug, in whatever form it’s presented, to a declining civilization, and a condition of individual integrity.  The medical profession should be ending cancer, not yielding to it with pain relief.  The goal should be to correct sickness, not bend the knee to pain and suffering.  We should be eating from the Tree of Eternal Life.  Trump got bit by the snake of deception here, and for me, it’s the off-ramp to continued support.  I’ve stood by Trump on everything for over ten years, and more.  But now, it’s time for all that to come to an end, over this issue.  Because for me, there is no compromise with evil.  Under any form that it presents itself.  And marijuana under any form that its presented is evil.  There are no blurred lines of consideration.  Trump got suckered by the same kind of people in the medical profession who suckered him on Covid.  And that isn’t forgivable.

Appendix: Cannabis Impact Metrics (Selected)

Metric	Finding	Population/Study	Key Citation
IQ decline (adolescent-onset, persistent)	~8 points from 13 to 38; broad deficits	Dunedin cohort (n≈1,037)	Meier et al., 2012; Nature News, 2012
Cannabis use disorder prevalence	≈2.8% past-year adults; ~30% of users with CUD	NESARC 2012–2013; national surveys	Hasin et al., 2015; Volkow et al., 2014
Psychosis risk (daily, high-potency)	Adj. OR ≈4.8; PAF up to 30–50% in some cities	EU-GEI multicenter case-control	Di Forti et al., 2019
Schizophrenia PARF (young males)	~15% in 2021; rising since 1990s	Denmark registry >7M	Hjorthøj et al., 2023; 2021
Pediatric exposures (Colorado)	Hospital rate ~2×; RPC calls ~5× increase	Colorado 2009–2015	Wang et al., 2016; ScienceDaily, 2016
Adolescent CHS ED encounters	Rates rose sharply 2016–2023	PHIS database, adolescents	Toce et al., 2025
Driving crash risk (acute use)	OR ≈1.2–1.9; higher with alcohol co-use	Meta-analyses 1982–2015	Asbridge et al., 2012; Rogeberg & Elvik, 2016

References

Asbridge, M., et al. (2012). Acute cannabis consumption and motor vehicle collision risk: systematic review and meta-analysis. BMJ, 344:e536. https://doi.org/10.1136/bmj.e536

Blanco, C., Hasin, D. S., Wall, M. M., et al. (2016). Cannabis Use and Risk of Psychiatric Disorders: Prospective Evidence. JAMA Psychiatry, 73(4), 388–395. https://doi.org/10.1001/jamapsychiatry.2015.3229

CRS (2023). HHS Recommendation to Reschedule Marijuana. IN12240. https://www.congress.gov/crs_external_products/IN/PDF/IN12240/IN12240.1.pdf

DEA (2024). Schedules of Controlled Substances: Rescheduling of Marijuana (NPRM). https://www.dea.gov/sites/default/files/2024-05/Scheduling%20NPRM%20508.pdf

Di Forti, M., et al. (2019). Contribution of cannabis use to variation in psychotic disorder incidence across Europe. The Lancet Psychiatry, 6(5), 427–436. https://doi.org/10.1016/S2215-0366(19)30048-3

ESPE Yearbook (2022). Development over time of PARF for CUD in schizophrenia in Denmark. https://www.espeyearbook.org/ey/0019/ey0019.14-8

Gillespie, N. A., et al. (2019). High-potency cannabis and incident psychosis: correcting the causal assumption. The Lancet Psychiatry, 6(6), 464–465.

Hjorthøj, C., et al. (2021). Development Over Time of PARF for CUD in Schizophrenia in Denmark. JAMA Psychiatry, 78(9), 1013–1019. https://doi.org/10.1001/jamapsychiatry.2021.1471

Hjorthøj, C., et al. (2023). Association between CUD and schizophrenia stronger in young males. Psychological Medicine. https://www.cambridge.org/core/journals/psychological-medicine/article/association-between-cannabis-use-disorder-and-schizophrenia-stronger-in-young-males-than-in-females/E1F8F0E09C6541CB8529A326C3641A68

King’s College London (2019). High potency cannabis linked to higher rates of psychosis. https://www.kcl.ac.uk/archive/news/ioppn/records/2019/march/high-potency-cannabis-linked-to-higher-rates-of-psychosis

Meier, M. H., et al. (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. PNAS, 109(40), E2657–E2664. https://doi.org/10.1073/pnas.1206820109

Nature News (2012). Drop in IQ linked to heavy teenage cannabis use. https://www.nature.com/articles/nature.2012.11278.pdf

Ohio Capital Journal (2025). Ohio Gov. Mike DeWine signs intoxicating hemp ban, new marijuana regulations into law. https://ohiocapitaljournal.com/2025/12/19/ohio-gov-mike-dewine-signs-intoxicating-hemp-ban-new-marijuana-regulations-into-law/

POLITICO (2025). Trump signs executive order to ease marijuana restrictions. https://www.politico.com/news/2025/12/18/trump-signs-executive-order-to-ease-marijuana-restrictions-00698021

Rogeberg, O. (2012). Correlations between cannabis use and IQ change in the Dunedin cohort are consistent with confounding. PNAS, 109(40), E2657–E2664. https://doi.org/10.1073/pnas.1215678110

Rogeberg, O., & Elvik, R. (2016). The effects of cannabis intoxication on motor vehicle collision revisited. Addiction, 111(8), 1348–1359. https://doi.org/10.1111/add.13347

Statehouse News Bureau (2025). Cannabis law changes, hemp beverage ban heads to Gov. DeWine. https://www.statenews.org/government-politics/2025-12-09/cannabis-law-changes-hemp-beverage-ban-heads-to-ohio-gov-dewine

Toce, M. S., et al. (2025). Emergency Department Visits for Cannabis Hyperemesis Syndrome Among Adolescents. JAMA Network Open, 8(7), e2520492. https://doi.org/10.1001/jamanetworkopen.2025.20492

USA Today/Cincinnati Enquirer (2025). Gov. Mike DeWine bans THC-infused drinks and products in Ohio. https://www.cincinnati.com/story/news/politics/2025/12/19/gov-mike-dewine-bans-thc-infused-drinks-and-products-in-ohio/87850131007/

Volkow, N. D., et al. (2014). Adverse Health Effects of Marijuana Use. NEJM, 370(23), 2219–2227. https://doi.org/10.1056/NEJMra1402309

Wang, G. S., Roosevelt, G., & Heard, K. (2016). Unintentional pediatric exposures to marijuana in Colorado, 2009–2015. JAMA Pediatrics, 170(9):e160971. https://doi.org/10.1001/jamapediatrics.2016.0971

Clinical Pediatrics (2019). The Continued Impact of Marijuana Legalization on Unintentional Pediatric Exposures in Colorado. https://doi.org/10.1177/0009922818805206

All About Lawyer (2025). Breaking Update: Federal Rescheduling to Schedule III. https://allaboutlawyer.com/is-marijuana-federally-legal-breaking-december-2025-update-on-federal-rescheduling-to-schedule-iii/

WLWT (2025). Ohio Gov. DeWine signs bill with line-item veto on marijuana/hemp changes. https://www.wlwt.com/article/ohio-gov-mike-dewine-hemp-marijuana-laws-line-item-veto/69823362

APA Ohio (2023). Summary of Ohio Issue 2 (Adult Use Cannabis). https://www.ohioplanning.org/aws/APAOH/asset_manager/get_file/883288

Rich Hoffman

Click Here to Protect Yourself with Second Call Defense https://www.secondcalldefense.org/?affiliate=20707